Citizen Portal
Sign In

Get Full Government Meeting Transcripts, Videos, & Alerts Forever!

Get email alerts on the Letters Of Authorization topic

No spam. Unsubscribe anytime.

Agency official stresses that letters of authorization are necessary for DMF review; Deborah Johnson to follow

Office of Pharmaceutical Quality (presenter) · July 30, 2026
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Summary

The presenter said letters of authorization (LOAs) grant permission for another party to reference a DMF, noted LOAs are sometimes missing after completeness assessment, and announced a follow-up session by Deborah Johnson on LOA details.

The agency presenter said letters of authorization (LOAs) are essential for reviewers to evaluate referenced DMFs and urged submitters to keep LOAs updated. She described LOAs as documents that "give another party the right to reference your Drug Master file" and said missing LOAs often surface after completeness assessment, delaying review.

The presenter announced that Deborah Johnson will give a dedicated talk later in the session to provide more information on preparing and using LOAs. She recommended updating LOAs over time and including copies both in referencing ANDAs and in referenced DMFs.